Inventor · disambiguated record
Malcolm K. Brenner
Also filed as: BRENNER MALCOLM · BRENNER MALCOLM K · BRENNER MALCOLM KEITH
14 granted patents·18 pending applications·215 citations·filing 1996–2025
91Inventor score
Files withBAYLOR COLLEGE MEDICINE20ADVISYS INC1BELLICUM PHARMACEUTICALS INC1BRENNER MALCOLM1BRENNER MALCOLM K1
Top patents by PatentIndex Score
32 records- 0196US9393292B2Methods for inducing selective apoptosisBAYLOR COLLEGE MEDICINE·Filed 2015·Granted Jul 19, 2016·22 cites·34 claims
- 0295US9089520B2Methods for inducing selective apoptosisBRENNER MALCOLM K·Filed 2011·Granted Jul 28, 2015·112 cites·24 claims
- 0389US10716818B2Oncolytic virotherapy and immunotherapyBAYLOR COLLEGE MEDICINE·Filed 2019·Granted Jul 21, 2020·6 cites·10 claims
- 0486US9493740B2Immunotherapy of cancer using genetically engineered GD2-specific T cellsBRENNER MALCOLM·Filed 2011·Granted Nov 15, 2016·25 cites·5 claims
- 0582US11896634B2Oncolytic virotherapy with helper-dependent adenoviral-based vectors expressing immunomodulatory moleculesBAYLOR COLLEGE MEDICINE·Filed 2018·Granted Feb 13, 2024·2 cites·13 claims
- 0681US10786549B2CD5 chimeric antigen receptor for adoptive T cell therapyBAYLOR COLLEGE MEDICINE·Filed 2016·Granted Sep 29, 2020·3 cites·19 claims
- 0781US2023270831A1Methods for inducing selective apoptosisBAYLOR COLLEGE MEDICINE·Filed 2022·Application pending·0 cites
- 0878US7241744B2Treating anemia in subjects by administration of plasmids encoding growth hormone releasing hormoneADVISYS INC·Filed 2002·Granted Jul 10, 2007·13 cites·1 claims
- 0971US11077176B2Methods for inducing selective apoptosisBAYLOR COLLEGE MEDICINE·Filed 2018·Granted Aug 3, 2021·0 cites·36 claims
- 1067US2020030421A1Methods for inducing selective apoptosisBAYLOR COLLEGE MEDICINE·Filed 2019·Application pending·0 cites
- 1165US2018271961A1Methods for inducing selective apoptosisBAYLOR COLLEGE MEDICINE·Filed 2018·Application pending·0 cites
- 1263US11547740B2Histone deacetylase (HDAC) inhibitor up-regulates car expression and targeted antigen intensity, increasing antitumor efficacyBAYLOR COLLEGE MEDICINE·Filed 2019·Granted Jan 10, 2023·0 cites·11 claims
- 1362US6344445B1Herpes virus vectors and their usesCANTAB PHARMACEUTICAL RES LTD·Filed 1996·Granted Feb 5, 2002·32 cites·16 claims
- 1461US2013323834A1Methods for inducing selective apoptosisBELLICUM PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 1557US12377147B2Reprogramming CD4 t cells into cytotoxic CD8 cells by forced expression of CD8ab and class 1 restricted t cell receptorsBAYLOR COLLEGE MEDICINE·Filed 2019·Granted Aug 5, 2025·0 cites·14 claims
- 1656US8178504B2Gene therapy expression of GHRH for increasing RBC count in subjectsDRAGHIA-AKLI RUXANDRA·Filed 2007·Granted May 15, 2012·0 cites·10 claims
- 1755US2021077530A1Auto/allo-immune defense receptors for the selective targeting of activated pathogenic t cells and nk cellsBAYLOR COLLEGE MEDICINE·Filed 2019·Application pending·0 cites
- 1855US2023210901A1Overcoming the tumor microenvironment for cell therapy by targeting myeloid derived suppressor cells through a trail-r2 specific receptorBAYLOR COLLEGE MEDICINE·Filed 2021·Application pending·0 cites
- 1955US2022000920A1Auto/allo-immune defense receptors for the selective targeting of activated pathogenic t cells and nk cellsBAYLOR COLLEGE MEDICINE·Filed 2021·Application pending·0 cites
- 2054US2025269032A1REPROGRAMMING CD4 T CELLS INTO CYTOTOXIC CD8 CELLS BY FORCED EXPRESSION OF CD8aB AND CLASS 1 RESTRICTED T CELL RECEPTORSBAYLOR COLLEGE MEDICINE·Filed 2025·Application pending·0 cites
- 2153US10279009B2Histone deacetylase (HDAC) inhibitor up-regulates car expression and targeted antigen intensity, increasing antitumor efficacyBAYLOR COLLEGE MEDICINE·Filed 2014·Granted May 7, 2019·0 cites·15 claims
- 2253US2020405811A1Cd5 chimeric antigen receptor for adoptive t cell therapyBAYLOR COLLEGE MEDICINE·Filed 2020·Application pending·0 cites
- 2351US11266726B2Compositions and methods for the treatment of HER2-expressing solid tumorsUS HEALTH·Filed 2016·Granted Mar 8, 2022·0 cites·14 claims
- 2449US2022387530A1Oncolytic virotherapy and immunotherapyBAYLOR COLLEGE MEDICINE·Filed 2019·Application pending·0 cites
- 2547US2003220284A1Delivery of adenoviral DNA in a liposomal formulation for treatment of diseaseFiled 2003·Application pending·0 cites
- 2644US2017027988A1Immunotherapy of cancer using genetically engineered gd2-specific t cellsBAYLOR COLLEGE MEDICINE·Filed 2016·Application pending·0 cites
- 2744US2014086888A1Ebv-specific cytotoxic t-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (npc)HESLOP HELEN E·Filed 2011·Application pending·0 cites
- 2844US2003083289A1Herpesvirus vectors and their usesFiled 2002·Application pending·0 cites
- 2944US2003148982A1Bi-spcific chimeric T cellsFiled 2002·Application pending·0 cites
- 3042US2013071414A1Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignanciesDOTTI GIANPIETRO·Filed 2012·Application pending·0 cites
- 3141US2019263928A1Adaptive chimeric antigen receptor t-cell designBAYLOR COLLEGE MEDICINE·Filed 2017·Application pending·0 cites
- 3233US2020016207A1TRANSGENIC c-MPL PROVIDES LIGAND-DEPENDENT CO-STIMULATION AND CYTOKINE SIGNALS TO TCR-ENGINEERED T CELLSBAYLOR COLLEGE MEDICINE·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Malcolm K. Brenner files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →